Literature DB >> 9445053

Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage.

S André1, B Seed, J Eberle, W Schraut, A Bültmann, J Haas.   

Abstract

DNA vaccination elicits humoral and cellular immune responses and has been shown to confer protection against several viral, bacterial, and parasitic pathogens. Here we report that optimized codon usage of an injected DNA sequence considerably increases both humoral and cellular immune responses. We recently generated a synthetic human immunodeficiency virus type 1 gp120 sequence in which most wild-type codons were replaced with codons from highly expressed human genes (syngp120). In vitro expression of syngp120 is considerably increased in comparison to that of the respective wild-type sequence. In BALB/c mice, DNA immunization with syngp120 resulted in significantly increased antibody titers and cytotoxic T-lymphocyte reactivity, suggesting a direct correlation between expression levels and the immune response. Moreover, syngp120 is characterized by rev-independent expression and a low risk of recombination with viral sequences. Thus, synthetic genes with optimized codon usage represent a novel strategy to increase the efficacy and safety of DNA vaccination.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9445053      PMCID: PMC124631     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

Review 1.  Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo.

Authors:  L Coney; B Wang; K E Ugen; J Boyer; D McCallus; V Srikantan; M Agadjanyan; C J Pachuk; K Herold; M Merva
Journal:  Vaccine       Date:  1994-12       Impact factor: 3.641

2.  Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA.

Authors:  G Nasioulas; A S Zolotukhin; C Tabernero; L Solomin; C P Cunningham; G N Pavlakis; B K Felber
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

3.  HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.

Authors:  C Bruck; C Thiriart; L Fabry; M Francotte; P Pala; O Van Opstal; J Culp; M Rosenberg; M De Wilde; P Heidt; J Heeney
Journal:  Vaccine       Date:  1994-09       Impact factor: 3.641

4.  Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.

Authors:  G Pantaleo; S Menzo; M Vaccarezza; C Graziosi; O J Cohen; J F Demarest; D Montefiori; J M Orenstein; C Fox; L K Schrager
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

5.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  Y Cao; L Qin; L Zhang; J Safrit; D D Ho
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

6.  Simian immunodeficiency virus DNA vaccine trial in macaques.

Authors:  S Lu; J Arthos; D C Montefiori; Y Yasutomi; K Manson; F Mustafa; E Johnson; J C Santoro; J Wissink; J I Mullins; J R Haynes; N L Letvin; M Wyand; H L Robinson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

7.  Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein.

Authors:  M Sedegah; R Hedstrom; P Hobart; S L Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

Review 8.  Toward an understanding of the correlates of protective immunity to HIV infection.

Authors:  B F Haynes; G Pantaleo; A S Fauci
Journal:  Science       Date:  1996-01-19       Impact factor: 47.728

9.  Protection against papillomavirus with a polynucleotide vaccine.

Authors:  J J Donnelly; D Martinez; K U Jansen; R W Ellis; D L Montgomery; M A Liu
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

10.  Evidence that HIV-1 Rev directly promotes the nuclear export of unspliced RNA.

Authors:  U Fischer; S Meyer; M Teufel; C Heckel; R Lührmann; G Rautmann
Journal:  EMBO J       Date:  1994-09-01       Impact factor: 11.598

View more
  115 in total

1.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques.

Authors:  Lauren A Hirao; Ling Wu; Abhishek Satishchandran; Amir S Khan; Ruxandra Draghia-Akli; Adam C Finnefrock; Andrew J Bett; Michael R Betts; Danilo R Casimiro; Niranjan Y Sardesai; J Joseph Kim; John W Shiver; David B Weiner
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

4.  HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Authors:  Bimal K Chakrabarti; Marie Pancera; Sanjay Phogat; Sijy O'Dell; Krisha McKee; Javier Guenaga; James Robinson; John Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-19       Impact factor: 2.205

5.  Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device.

Authors:  Dinah H Amante; Trevor R F Smith; Janess M Mendoza; Katherine Schultheis; Jay R McCoy; Amir S Khan; Niranjan Y Sardesai; Kate E Broderick
Journal:  Hum Gene Ther Methods       Date:  2015-08       Impact factor: 2.396

6.  Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B.

Authors:  Hyun-Jeong Ko; Sung-Youl Ko; Yeon-Jeong Kim; Eun-Gae Lee; Sang-Nae Cho; Chang-Yuil Kang
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

7.  Protective immunity against tularemia provided by an adenovirus-vectored vaccine expressing Tul4 of Francisella tularensis.

Authors:  Ravinder Kaur; Shan Chen; Maria T Arévalo; Qingfu Xu; Yanping Chen; Mingtao Zeng
Journal:  Clin Vaccine Immunol       Date:  2012-01-25

8.  Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.

Authors:  Shixia Wang; Jessica Taaffe; Christopher Parker; Alicia Solórzano; Hong Cao; Adolfo García-Sastre; Shan Lu
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

9.  Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.

Authors:  L Deml; A Bojak; S Steck; M Graf; J Wild; R Schirmbeck; H Wolf; R Wagner
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques.

Authors:  Jian Yan; Kristina Harris; Amir S Khan; Ruxandra Draghia-Akli; Duane Sewell; David B Weiner
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.